Runben Biotechnology Co

Runben Biotechnology Co Financial Leverage

The Financial Leverage (Equity Multiplier) of Runben Biotechnology Co (603193.SS) as of Oct 16, 2026 is 1.05. In the previous year, Financial Leverage (Equity Multiplier) was 1.07 — a change of -1.33% (lower).

Financial Leverage

1.05

YoY

-1.33%

Last updated:

Financial Leverage (Equity Multiplier) of Runben Biotechnology Co is 2025 1.05 . Financial Leverage (Equity Multiplier) of Runben Biotechnology Co was 2024 1.07 . It decreases by -1.33% lower compared to the previous year.

The Runben Biotechnology Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.20 CNY
Jan 1, 2020
1.11 CNY
Jan 1, 2021
1.15 CNY
Jan 1, 2022
1.14 CNY
Jan 1, 2023
1.05 CNY
Jan 1, 2024
1.07 CNY
Jan 1, 2025
1.05 CNY
The Runben Biotechnology Co Financial Leverage history
YEARFinancial LeverageYoY
1.05-1.33%
1.07+1.52%
1.05-8.01%
1.14-0.74%
1.15+4.12%
1.11-7.67%
1.20—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Runben Biotechnology Co Stock analysis

What does Runben Biotechnology Co do? Runben Biotechnology Co Ltd, trading under the ticker symbol 603193.SS and identified by ISIN CNE100006DK5, is a Chinese enterprise operating within the Consumer Staples sector, specifically in the consumer products industry. Headquartered in Guangzhou, Guangdong, the company has established itself as a specialized manufacturer and distributor of personal care items, with a notable focus on mosquito repellents and baby care solutions. As of the latest available data, the firm employs 917 full-time staff members who support its extensive research, development, manufacturing, and sales operations. Runben Biotechnology officially entered the public markets via an initial public offering on October 17, 2023, marking a significant milestone in its corporate development and providing greater visibility into its financial and operational strategies. The company’s product portfolio is strategically divided into three primary categories: mosquito repellent products, baby care products, and essential oil-based items. Among its best-selling offerings are electric mosquito repellent liquids and DEET-based repellent solutions, which cater to the growing consumer demand for effective and safe pest control measures. In the personal care segment, the firm produces a diverse range of skincare and hygiene products, including lipsticks, face creams, facial cleansers, and general skincare creams, targeting consumers who prioritize gentle and specialized formulations. The company’s business model relies heavily on digital commerce channels, utilizing internet sales platforms to reach its customer base directly. This includes online direct sales, distribution through major online platforms, and agency sales models that facilitate broader market penetration. By leveraging these e-commerce strategies, Runben Biotechnology has been able to maintain a strong presence in the domestic Chinese market, where the majority of its revenue is generated. The firm’s commitment to innovation in product formulation, combined with its agile distribution network, positions it as a competitive player in the crowded consumer goods landscape. Through its continued investment in research and development, the company aims to expand its product lines and enhance the quality of its offerings, ensuring it meets the evolving needs of modern consumers. The integration of traditional manufacturing expertise with modern digital sales tactics allows Runben Biotechnology to adapt quickly to market trends and maintain customer loyalty. As it continues to grow, the company remains focused on delivering high-quality, safe, and effective products that address everyday consumer concerns, particularly in the areas of personal hygiene and family care. Runben Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Runben Biotechnology Co stock

Financial Leverage (Equity Multiplier) of Runben Biotechnology Co is 1.05 in 2025.

Financial Leverage (Equity Multiplier) of Runben Biotechnology Co changed from 1.07 to 1.05, representing a -1.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Runben Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Runben Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Runben Biotechnology Co

All Key Metrics — Runben Biotechnology Co